|
|
| Courses | Phar 6122 |
|
| NOTE: Landmark Trials are those trials which are of substantive influence on the clinical practice of cardiovascular medicine. Trials under the heading of Enrichment are to supplement information. As a student of Phar. 6122, you should be quite familiar with their Objectives, Methods, Results and Interpretation of those trials. Additional trials are added which may augment the student's understanding of the area but may not have been as influential as others in contemporary practice. | ||
Topic/Reference Status |
html Version | Description |
| Hypertension | ||
| Landmark Trials for Hypertension | ||
| html | Study Description | |
| ACCOMPLISH | NA | Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients: the B-A combination was superior to B-HCT in reducing CV events in hypertensives at high risk for such events. |
| a.ASCOT-BPLA Article b. ASCOT-BPLA editorial |
NA | (Blood pressure arm of ASCOT. Thearzede and β-blockers vs CCBA and ACE) |
| HYVET | Treatment of Hypertension in Patients 80 Yeasr of Age or Older: Treatment of the old-old, remains beneficial with diuretic with or without ACE inhibitor. | |
a. ON Target |
Telmisartan, Ramipril or Both in patients with high risk for vascular Events: Double blind randomized study with primary outcome of CV death, MI, Stroke or hospitalization for HF. Telmisartan equal to ramipril in pts with vascular disease or high risk diabetes but was associated with less angioedema. The combination was associated with more AE's without increase in benefit. |
|
| NA | (valsartan vs. amlodipine for prompt blood pressure control) | |
| Enrichment Trials for Hypertension | ||
| html | Study Description | |
| a.
AASK b. article c. editorial |
AASK Trial | (ISH, nitrendipine + others vs PL) |
| ABCD Trial | ABCD Trial | (nisoldipine vs enalapril in preventing type 2 DM complications) |
| ANBP2 | NA | (Australia National Blood Pressure-2 Trial) |
| ALLHAT | ALLHAT Trial | (chlorthalidone vs lisinopril, and amlodipine) |
| BENEDICT | ||
| Blood Pressure Trialists' collaboration |
Effects of different blood-pressure-lowering regimens on major cardiovascular events |
|
| NA | ||
| DETAIL | ||
| DREAM Trial | NA | Ramapril vs. Placebo in patients with either IFG or IGT but not diabetes for reduction in CV events |
| a.
EUROPA Trial b. EUROPA Correspondence |
a.
NA b. NA |
(felodipine + ASA + goal BP) |
| NA | (Type 2 Diabetes and CV Risk) | |
| a. HOPE ACE b. Micro-HOPE c. HOPE Vitamin E d. HOPE Ambulatory vs. Office BP |
a. HOPE
ACE Trial b. Micro-HOPE c. HOPE Vitamin E Trial d. NA |
a.
Ramapril vs. Placebo in High Risk Patients b. HOPE for type 2 diabetics only c. HOPE with Vitamin E component d. Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures |
| HOT Trial | HOT Trial | |
| IDNT | IDNT Trial | (PL, irbesartan, amlodipine in type 2 DM nephropathy) |
| INVEST | NA |
A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease |
| IRMA II | IRMA II Trial | (irbesartan in type 2 DM + microalbuminuria) |
| a. LIFE b. LIFE Trial Commentary c. LIFE Trial Diabetes Patients |
LIFE Trial | (losartan vs. atenolol)
|
| NA | MIDAS Trial | (isradipine vs HCTZ in progression of mean max IMT) |
| NORDIL | NA |
Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension |
| a.
PEACE Trial b. PEACE Editorial |
a.
NA b. NA |
a. b. |
| NA | (peridndopril and indapamide to lower BP which had a larger risk reduction of recurrent stroke or TIA) | |
| RENAAL Trial | RENAAL Trial | (losartan in type 2 DM + nephropathy)
|
| SHEP Stroke | SHEP Trial | (captopril vs atenolol in type 2 DM) |
| Syst-China Trial | SYST-China Trial | (doxazocin vs chlorthalidone) |
| Syst-Eur Trial | SYST-EUR Trial | (ISH, nitrendipine + others vs PL) |
| NA | TOMHS Trial | (ramipril vs amlodipine vs metoprolol in African Americans) (Management of High Blood Pressure in African Americans |
| UKPDS 39 Trial | UKPDS 39 Trial | (chlorthalidone + atenolol in ISH) |
| B-Blocker meta-analysis | NA | Beta-blocker meta-analysis Lancet 2005 |
| Lipids | ||
| Landmark Trials for Lipids | ||
| html | Study Description | |
| NA | Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia: In patients with FH, the addition of ezetimibe to simvastatin did not result in significant differences in the change in intima-media thickness vs. simvastatin alone. |
|
| NA | Effects of long-term fenofibrate therapy on type 2 diabetes and CV events. |
|
| a. HPS b. HPS Diabetes Substudy c. HPS Antioxidant |
HPS | (Simvastatin vs PL) |
|
Rosuvastatin to prevent vascular events in men and women with elevated CRP: In this trial of apparently healthy people without hyperlipidemia but elevated hsCRP, rosuvastatin significantly reduced major CV events. | |
| a.
PROVE-IT b. PROVE-IT Editorial |
PROVE IT | (Atorvastatin 80 mg vs. Pravastatin 40 mg in ACS) |
| TNT Editorial | NA | Atorvastatin 10mg vs Atorvastatin in stable coronary disease |
| TNT Study | NA | The evaluation of intensive vs. moderate lipid lowering by statins for patients with chronic CAD (atorvastatin 80 vs. 10mg) |
| VA-HIT | VA-HIT | (gemfibrozil vs PL secondary prevention) |
|
a.
Grundy 2004
White Paper:
Circulation b. Grundy 2005 Metabolic Syndrome |
NA
NA |
Proposed
revision to NCEP ATP III guidelines -new targets Diagnosis and Management of the Metabolic Syndrome |
| WOSCOPS | WOSCOPS | (Pravastatin primary Prevention) |
| Enrichment Trials for Lipids | ||
| html | Study Description | |
| AFSCAPSTexCAPS | AFSCAPS/TexCAPS | (Lovastatin primary Prevention) |
| ALLHAT-LLT | ALLHAT-LLT | (pravastatin vs usual care) |
| ASCOT-LLT | NA | (Lipid lowering arm. Atorvastatin 10 mg vs PL) |
| Phase Z of the A to Z trial | (Early Intensive vs. a Delayed Conservative Simvistatin Strategy in Patients With Acute Coronary Syndromes) | |
| Asteroid Trial | (Effect of Very High-Intensity statin Therapy on Regression of Coronary Atherosclerosis) | |
| BIP Trial | BIP Study | (Benzfibrate secondary Prevention) |
| CARDS | NA | Atorvastatin 10mg vs. placebo in Type 2 diabetes. |
| 4S Trial | (Simvastatin secondary Prevention) | |
| a.
CARE b. CARE Diabetes |
CARE | (Pravastatin primary Prevention) |
| a. IDEAL |
NA | Comparison between High Dose Atorvastatin (80mg) vs. moderate dose Simvastatin (20mg) for secondary prevention of Coronary events |
| a.
LIPID b. LIPID Trial Follow-up |
LIPID | (Pravastatin primary Prevention) |
| MIRACL | MIRACL | (atorvastatin vs post ACS) |
| Post Bypass Trial | Post-Bypass Study | (Pravastatin secondary prevention) |
| PROSPER | PROSPER Trial | (Pravastatin in elderly CVD) |
| REVERSAL | (Atorvastatin 80 mg vs. Pravastatin 40 mg for coronary artery atheroma burden) | |
| McKenny American Journal of Cardiology 2006 NLA Statin Safety Assesment | NLA Statin Safety Assesment by McKenney et al. American Journal of Cardiology 2006; 97: 89-94 |
(Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force) Read both tables and recommendations |
| Anticoagulation and Thrombolytic Studies | ||
| Landmark Trials for Anticoagulation and Thrombolytic Studies | ||
|
|
html |
Study Description |
| ASSENT-3 | ASSENT-3 | (TNK ase + Enoxaparin vs TNK + UFH, vs TNKase + abciximab + UFH) |
| NA | (clopedigrel vs ASA) | |
| CREDO | NA | Early combination therapy (Clopedigril + ALA with PCI) |
| CURE Trial | CURE Trial | (clopedigrel + ASA vs. ASA) |
| ESSENCE | ESSENCE | (Enoxaparin vs UFH) |
| GUSTO IV | GUSTO IV | ACS (PL vs abciximab 24 hrs vs abciximab 48 hrs) |
| Enoxaparin vs. UFH in high-risk NSTEMI patients. | ||
| NA | TIMI IIB | (enoxaprin vs UFH) |
| Enrichment Trails for Anticoagulation and Thrombolytic Studies | ||
| html | Study Description | |
| NA | ASSENT-2 | (SK vs t-PA over 3 hours) |
| Aspirin use in Women | Aspirin in Primary Prevention for Women | |
| CLARITY-TIMI28 trial | Clopidogrel to Aspirin and Fibrinobtic Therapy for STEMI patient | |
| CRUSADE STUDY | NA | |
| NA | EPILOG | (abciximab and low dose heparin vs PL w/standard dose heparin vs abciximab) |
| NA | FRIC | (LMWH SC vs UFH) |
| NA | FRISC II | (LMWH SC vs standard UFH) |
| NA | GISSI-1 | (St-PA vs. TNKase) |
| NA | GISSI-2 | (SK vs t-PA, APSAC) |
| NA | GUSTO | (SK vs SK + ASA vs ASA vs Placebo) |
| GUSTO-III | GUSTO-III | (SK vs Placebo) |
| NA | GUSTO IIB | (angioplasty vs accelerated thrombolytic therapy) |
| GUSTO V |
|
AMI (retaplace vs 1/2 dose r-PA + abciximab) |
| NA | ISIS-2 | (SK vs t-PA over 3 hours) |
| NA | ISIS-3 | (SK + sq or IV hep vs t-PA over 90 minutes) |
| NA | SPAF Trials | (stroke prevention w/ASA or warfarin in AF) |
| NA | Ximelagatran vs. Warfarin in patients with nonvalvular atrial fibrillation | |
| NA | TIMI-1 | (r-PA vs Alteplase) |
| AMI Therapy | ||
| Landmark Trials for AMI | ||
| |
html |
Study Description |
| CAPRICORN | CAPRICORN | Carvedilol post AMI in patients with low EF |
| EPHESUS | NA | (eplerenone vs PL post AMI) |
| a.
VALIANT b. VALIANT Editorial |
NA | Valsartan, captopril or both |
| Enrichment Trials for AMI | ||
| html | Study Description | |
| NA | Summary of ACE Inhibitors Post AMI | Table of Studies with ACE inhibitors Post AMI |
| NA | B-Blockers Meta analysis | B-blockers post AMI-meta analysis |
| NA | Summary of Beta-blockers Post AMI | (Tables of beta-blockers Post MI) |
| HART II Study | NA | LMWH and Lytics with AMI |
| OPTIMAAL Trial | OPTIMAAL Trial | Valsartan-captopril post MI |
| Antiarrhythmics | ||
| html | Study Description | |
| a.
AFFIRM TRIAL b. AFFIRM FOLLOW UP |
AFFIRM Trial | (Rate control vs Rhythm control in AF patients) |
| ARREST TRIAL | ARREST Trial | (amiodarone in cardiac arrest) |
| NA | CAST and CAST II Trials I | (Flecainide, encainide, morcizine post MI) |
| Enrichment Trials for Antiarrhythmics | ||
| html | Study Description | |
| NA | Amiodarone Post Surgery | |
| NA | AVID | (ICD vs amiodarone and sotalol in VAs) |
| NA | CAMIAT | (amiodarone post MI) |
| Drug Induced QT Prolongation Review | (Roden NEJM 2004) | |
| NA | EMIAT | (amiodarone post MI) |
| NA | ESVEM | (Sotalol and Holter Monitoring vs EPS) |
| LIFE -Trial-Afib analysis | NA | (LIFE trial analysis for endpoints of related to Afib. Angiotensin II Receptor Blockade Reduces New-Onsset Atrial Fibrillation and Subsequent Stroke Compared to Atenolol.) |
| NA | MADIT | (ICD w/ventricular arrhythmias (VAs) |
| SCD HeFT Trial | NA | (conventional therapy and placebo vs. conventional therapy and amiodarone vs. convention therapy and ICD in HF patients with NYHA II or II and EF <35%) |
| NA | Summary Table of Key Trials | |
| NA | SWORD | (sotalol in post MI and LVD) |
| Congestive Heart Failure | ||
| Landmark Trials for Congestive Heart Failure | ||
| html | Study Description | |
| a.
CHARM Overall b. CHARM Added c. CHARM Alternative d. CHARM Preserve |
CHARM Series | Added, Overall, Preserved, Alleviate |
| COMET | NA | (IR metoprolol vs. carvedilol in CHF) |
| COPERNICUS | COPERNICUS | (cavedilol vs PL) |
| The DIG Study | The Dig Study | (Digoxin vs PL) |
| EPHESUS | NA | (eplerenone vs PL post AMI) |
| MERIT-HF | MERIT-HF | (metroprolol CR-XL vs. PL) |
| RALES | RALES | (spironolactone vs. PL) |
| NA | SOLVD | (enalapril vs PL) |
| Val-HEFT | Val-HEFT | valsartan vs standard therapy) |
| VHeFT II | VHeFT II | (enalapril vs hydralazine + ISDN in HF patients) |
| Enrichment Trials for Congestive Heart Failure | ||
| html | Study Description | |
| NA | (ISDN + hydralazine in African American NYHA III and IV HF patients) | |
| ATLAS | ATLAS Trial | (Lisinopril high dose vs low dose) |
| Bisoprolol and Enalapril for CHF | NA | Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence |
| NA
|
|
|
| CIBIS-II Trial | CIBIS- II | (bisoprolol vs PL) |
| NA | CONSENSUS | (enalapril vs PL) |
| a.
ELITE b. ELITE II |
ELITE | a.
Losartan vs captopril in patients with HF where Losartan appeared to have
benefits, b. Losartan vs. captopril in HF patients where no difference existed |
| PRAISE | PRAISE | (amlodipine vs standard therapy) |
| Stains- Survival in HF | NA | |
| VMAC | NA | IV Nesiritide vs. IV nitroglycerine for decompensated acute heart failure |
| Miscellaneous Studies | ||
| Enrichment Trials for Miscellaneous Studies | ||
| html | Study Description | |
| APC study | Study Description: CV risk with Celecoxib | |
| Atrial Arrhythmia | Primer on Atrial Arrhythmia | |
|
Cardiac Art 1 Cardiac Art 2 Cardiac Art 3 Cardiac Art 4 Cardiac Art 5 Cardiac Art 6 |
Primers on Cardiac function at cellular level | |
| Cardiovascular effects and interactions with Herbals | Cardiovascular effects and interactions with Herbals | |
| ECG Introduction | Primer on rhythm strip recognition and ECG information | |
| ECG Terminology | Primer on ECG Terminology | |
| ESPS2 | ||
| Genomics |
|
Antihypertensives |
| Inheritance and Drug Response | Genomics and Medicine NEJM 2003 | |
| Pharmacogenomics | - Drug Disposition, Drug Targets, and Side Effects | |
| Tachycardis Part 1 | Primer on Broad Complex Tachycardia Part 1 | |
| Tachycardias Part 2 | Primer on Broad Complex Tachycardia Part 2 | |
| [Phar 6122 Homepage] [College of Pharmacy Homepage] [University of Minnesota Homepage] |
| The University of Minnesota is an equal opportunity educator and employer. The
views and opinions expressed in this page are strictly those of the page author. The
contents of this page have not been reviewed or approved by the University of Minnesota. |
